StockData
Viridian Therapeutics, Inc.DE logo

Viridian Therapeutics, Inc.DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30257% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.DE price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Viridian Therapeutics, Inc.DE's price to book ratio was 5.3× on Nov 11, 2026, against 5.2× a year earlier. Over the last 5 years it ranged from 1.3× to 5.4×, with a median of 2.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.3×+0.3
2025Dec 31, 20255.1×+2.9
2024Dec 31, 20242.1×−1.2
2023Dec 29, 20233.4×+0.5
2022Dec 30, 20222.9×+1.0
2021Dec 31, 20211.9×−1.1
2020Dec 31, 20203.0×+2.3
2019Dec 31, 20190.6×−0.9
2018Dec 31, 20181.5×−4.3
2017Dec 29, 20175.9×+5.1
2016Dec 30, 20160.8×+0.1
2015Dec 31, 20150.6×+0.5
2014Oct 31, 20140.1×–

More Viridian Therapeutics, Inc.DE figures

See a number that looks wrong?